Surveillance of hematopoietic chimerism following hematopoietic SCT (HSCT) with nonmyeloablative (NMA) preparative regimens is standard to assess the need for clinical intervention. Monitoring of donor chimerism following HSCT with myeloablative (MA) preparative regimens is, however, not considered useful because engraftment is thought to occur rapidly and consistently. This study compares the timing of donor hematopoietic cell engraftment in patients undergoing NMA conditioning with fludarabine and TBI with those receiving MA conditioning with BU-or TBI-based regimens. Achievement of X90% donor leukocyte chimerism occurred rapidly and consistently in all three groups and time to achievement of X90% donor T cells was similar among the three groups (P ¼ 0.57). Achievement of X90% donor leukocyte chimerism was not associated with risk of acute or chronic GVHD, graft rejection, relapse or all cause mortality in multivariate analyses. Donor T-cell chimerism of X90% was significantly associated with development of extensive chronic GVHD. The value of routine surveillance of chimerism following any of the preparative regimens used in this study should be reevaluated.
Introduction
Hematopoietic chimerism is defined by the presence of lymphohematopoietic cells of nonhost origin. 1 Following hematopoietic SCT (HSCT), hematopoietic chimerism can be monitored in the recipient's peripheral blood or BM by analysis of donor-specific alleles or STR using PCR or fluorescent in-situ hybridization. Myeloablative (MA) preparative regimens for allogeneic transplantation are designed to eradicate the lymphohematopoietic system of the recipient, which is subsequently replaced by donor cells. In contrast, the so-called 'nonmyeloablative (NMA) regimens' are not designed to directly ablate the host's hematopoiesis and immunity, 2 but rather to provide sufficient immunosuppression to prevent rejection of donor cells and thus enable their engraftment. Donor immune cells then eradicate normal and malignant host hematopoiesis. NMA regimens were developed to treat hematological disorders in patients of advanced age or with medical comorbidities who are not considered appropriate candidates for more intense and toxic conditioning 3 and were initially designed to achieve mixed hematopoietic chimerism. The surveillance of chimerism after NMA preparative regimens is standard and is used to identify patients at risk for graft rejection, relapse, and acute and chronic GVHD, and to assess the need for and timing of donor lymphocyte infusions.
Monitoring of donor chimerism following HSCT with MA preparative regimens, however, is not considered useful because engraftment is thought to occur rapidly and consistently. The 2001 workshop of the American Society of Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry recommended against the routine assessment of chimerism in this group of patients. 1 Some recent studies have confirmed these findings and recommendations; 4, 5 however, a recent report found that 28% of patients showed mixed chimerism at day 90 following MA HSCT, and these patients had worse outcomes than those with complete chimerism. The authors concluded that the detection of mixed chimerism following MA HSCT should prompt clinical intervention. 6 To better understand the patterns of chimerism following NMA and MA HSCT, we compared the patient characteristics, engraftment kinetics and clinical outcomes of patients who underwent MA and NMA HSCT for hematopoietic malignancies. No direct comparison of chimerism following MA and NMA transplantation has been previously reported. Our goals were to compare the speed and extent of donor chimerism between BU-based MA, TBI-based MA and NMA preparative regimens consisting of fludarabine (Flu) and TBI and to assess the usefulness of routine chimerism analysis following MA and NMA transplantation.
Patients and methods

Patient population
We reviewed the serial chimerism data for 233 consecutive patients who underwent allogeneic HSCT for hematological malignancies from 1 May 2000 through 31
December 2007 at the Taussig Cancer Institute of the Cleveland Clinic. Chimerism analyses were routinely performed at 28, 42, 56, 70, 84 and 100 days following transplantation, then every 2 months for two occurrences, every 3 months for four occurrences, every 4 months for six occurrences and then yearly. Eighteen patients who did not have appropriately timed chimerism studies were excluded from the analysis. Three patients who received MA preparation, which was not BU-or TBI-based, two patients who received NMA regimens other than Flu/TBI and three NMA patients who received BM rather than peripheral blood were excluded. The remaining 207 patients were included in our analysis.
Conditioning regimens
The 207 patients were categorized into three groups: patients undergoing MA transplantation with BU-based conditioning (MA-BU, n ¼ 72), patients undergoing MA transplantation with a TBI-based regimen (MA-TBI, n ¼ 41) and patients undergoing NMA transplantation following Flu/TBI (NMA, n ¼ 94). Among the 94 patients in the NMA group, 42 received a dose of 200 Gy TBI and 52 received a dose of 400 Gy (in two fractions) as part of sequential studies. The clinical characteristics of the patients in each group are detailed in Table 1 . The conditioning regimens are described in Table 2 .
GVHD prophylaxis GVHD prophylaxis regimens were categorized as: (1) mycophenolate mofetil with CsA or tacrolimus (FK506), (2) MTX with CsA or FK506 and (3) CsA or FK506 alone.
Chimerism analysis
Total leukocyte and T-cell chimerism were assessed using a STR assay by PCR using peripheral blood. DNA was extracted by machine (Roche Magna-Pure LC, Indianapolis, IN, USA), and T cells were isolated using RosetteSep (StemCell Technologies, Vancouver, British Columbia, Canada). The ABI 310 Genetic Analyzer (GMI, Inc, Ramsey, MN, USA) was used to run the buffy coat and separated T-cell samples for the STR analysis.
Statistical considerations
Baseline characteristics were summarized by transplant group. Continuous variables were summarized as the mean, s.d. and range. Categorical variables were summarized as frequency counts and percentages. The time to achieve 90% donor total leukocyte and T-cell chimerism was estimated using the Kaplan-Meier method and compared among the three groups with the log-rank test. When the overall test was significant, pairwise comparisons of each group were performed to determine which groups differed. For overall tests, Po0.05 was used to indicate statistical significance. For pairwise comparisons, Po0.017 (0.05/3) was used to indicate statistical significance. Cox proportional hazards analysis was used to determine whether any of the baseline characteristics were associated with T-cell or total leukocyte chimerism. All baseline characteristics that are shown in Table 1 were included in this analysis. Transplant group and all variables that were significant in univariate analysis at Pp0.10 were included in a multivariate model. The prognostic effect of total leukocyte and T-cell chimerism on post-transplant outcomes was assessed by analyzing chimerism as a time-dependent covariate in a Cox proportional hazards analysis. The analysis was performed twice for each outcome: once in a univariate setting where chimerism was the only variable examined and a second time adjusted for transplant type. Nine post-transplant outcomes were assessed: any acute GVHD, grades II-IV acute GVHD, grades III-IV acute GVHD, any chronic GVHD, extensive chronic GVHD, graft rejection, relapse, all-cause mortality and relapse mortality. All analyses were carried out using SAS software (SAS Institute Inc, Cary, NC, USA). A threshold of X90% donor leukocytes or T cells was chosen to reliably exceed the lower limit of sensitivity for recipient cells and to permit meaningful comparison to other published studies.
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Results
Rate of engraftment Influence of preparative regimen on total leukocyte chimerism. In the MA-BU, MA-TBI and NMA groups, the number of patients who never achieved X90% donor leukocyte chimerism were 1 (1. 1%), 2 (4.9%) and 1 ( Figure 1 ). These medians were identical to the medians for each group at which the first chimerism studies were drawn; that is, the NMA patients had their initial chimerism study performed at a median of 2 days earlier than the MA-BU patients and 3 days earlier than the MA-TBI patients.
Influence of preparative regimen on T-cell chimerism. In the MA-BU, MA-TBI and NMA groups, the number of patients who failed to reach X90% T-cell chimerism were 9 (12.5%), 4 (9.8%) and 11 (11.7%), respectively. The time to achieve X90% donor T-cell chimerism was not statistically different among the three groups (P ¼ 0.57). The median number of days to X90% donor T-cell chimerism was 43 days (mean ± s.d. ¼ 88 ± 107, range ¼ 24-571) in Figure 2 ).
Other factors influencing total leukocyte chimerism. Several baseline characteristics reached statistical significance as prognostic factors for development of X90% donor total leukocyte chimerism in univariate analysis. Patients with lymphoma were more likely to achieve X90% chimerism compared with patients with ALL (hazard ratio (HR) ¼ 2.03, P ¼ 0.01). MA-prepared patients who received PBSC were more likely to achieve 90% donor chimerism compared with those who received BM (HR ¼ T-cell chimerism. Nine patients (4.3%) suffered graft rejection. The hazard of rejection was not significantly associated with donor chimerism (HR ¼ 32, P ¼ 0.13) whether adjusted or not for the three transplant groups. In univariate and multivariate analyses, patients who achieved X90% donor T-cell chimerism were more likely to develop chronic GVHD (HR ¼ 3.73, Po0.001; HR ¼ 3.79, Po0.001) and extensive chronic GVHD (HR ¼ 3.11, P ¼ 0.026; HR ¼ 3.08, P ¼ 0.027). Patients who achieved X90% donor T-cell chimerism were also somewhat more likely to develop grades III-IV acute GVHD in univariate (HR ¼ 1.95, P ¼ 0.07) and multivariate analyses (HR ¼ 1.91, P ¼ 0.08). Achievement of X90% T-cell chimerism was not significantly associated with relapse or mortality in univariate or multivariate analyses. The effect of T-cell chimerism on outcomes was analyzed separately for MA and NMA transplantation. Among MA recipients, X90% T-cell chimerism was marginally associated with a greater risk of any acute GVHD (HR ¼ 1.92, P ¼ 0.08) and chronic GVHD (HR ¼ 2.26, P ¼ 0.07). Among NMA patients, X90% T-cell chimerism was associated with a greater risk of Grades III-IV acute GVHD (HR ¼ 2.78, P ¼ 0.049), chronic GVHD (HR ¼ 8.95, P ¼ 0.003) and a marginally greater risk of extensive chronic GVHD (HR ¼ 6.48, P ¼ 0.07). No significant association with graft rejection or relapse was detected among either MA or NMA transplants.
Discussion
This study compares the timing of donor lymphohematopoietic cell engraftment in patients undergoing NMA conditioning with Flu/TBI with those receiving MA conditioning with BU-or TBI-based regimens. Flu plus 200 cGy TBI is the most widely used NMA regimen; Flu plus 400 cGy (in two fractions) TBI is also nonmyeloablative 8 and was not associated with more rapid leukocyte or T-cell chimerism or less rejection than with 200 cGy (data not shown). The slightly more rapid achievement of donor leukocyte chimerism measured in the NMA patients can be totally accounted for by the slightly earlier performance of these studies in this group, related in part to their outpatient visit schedule. Most importantly, all three groups achieved X90% donor leukocyte chimerism rapidly and consistently. Further, there was no statistically significant difference in time to achievement of X90% donor T cells among the groups, and nearly 90% of all patients achieved X90% T-cell chimerism.
These data conflict with an apparent general consensus that donor hematopoietic cell engraftment occurs less rapidly and less completely following NMA preparation compared with MA regimens. This perception may have developed from the purposeful establishment of 'mixed chimerism' in animal models and in humans following some NMA regimens, including low-dose TBI alone 3 or the combination of CY, anti-thymocyte globulin and thymic irradiation. 9 Stable mixed chimerism protects from GVHD and can be used as a platform for additional therapy including donor lymphocyte infusion to increase donor chimerism and augment antitumor effect. [9] [10] [11] This study demonstrates that Flu/TBI, the well-tolerated and most commonly used nonmyeloablative regimen, is similar to BU/CY and CY/TBI in achieving rapid lymphohematopoietic engraftment in most patients. Speed and extent of donor chimerism has been shown to be influenced by additional factors including primary diagnosis and previous treatment. 1 We attribute the greater achievement of X90% donor T-cell chimerism among lymphoma compared with myelodysplastic syndrome patients in this study to their being more heavily treated and therefore more immunosuppressed before transplant.
The results of this study also show that permanent eradication of the recipient lymphohematopoietic system does not always occur following MA regimens. Leukocytes, particularly T cells, were still detectable in many patients in this study, 4 weeks and longer after 'myeloablation.' Effective immunosuppression (with Flu/TBI and GVHD prevention medications) and large doses of CD34 þ cells result in rapid and consistent engraftment similar to those that follows directly MA regimens. The results reported here are similar to those reported by others. [2] [3] [4] [5] [6] [7] [12] [13] [14] These data undermine the use of the terms 'myeloablative' and 'nonmyeloablative'. As Deeg 15 has recently pointed out, all transplantations in patients with malignant hematological disorders are designed to be myeloablative in order to achieve disease eradication.
The results also raise questions concerning the utility of routine chimerism surveillance following NMA or MA regimens. Reports that assessment of donor chimerism levels among T cells predicts graft rejection, GVHD and relapse after NMA conditioning 16 have not led to compelling evidence that early interventions, on the basis of these studies, improve outcome compared with that achievable with performance of chimerism studies based on clinical circumstances, for example, persistent pancytopenia following transplantation. A limitation to our study and those of others, however, is that we did not analyze what interventions may have been prompted by the results of these chimerism studies, which may then have affected the patient's clinical outcome. As factors other than preparative regimen including primary diagnosis, previous treatment, stem cell source, cell dose, histocompatibility and GVHD prevention [1] [2] [3] [4] [5] [6] [7] [8] are important determinants of the speed and extent of donor chimerism, the conventional reliance on type of preparative regimen alone to determine whether to perform chimerism surveillance may be oversimplified. This study suggests the need for a fresh look at present indications for surveillance of chimerism following transplantation.
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